ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
This is a safety, feasibility and pharmacokinetic study to confirm that the recommended safe
dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a
previous phase I study is also safe and feasible in the target population of patients with
CRPC.